Nivira Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Nivira Exports Pharmaceutical Export Portfolio Dataset — 4 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Nivira Exports — Pharmaceutical Exporter Profile (2026) | 4 Products, $1.1M Trade | TransData Nexus

Nivira Exports

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $1.1M Total Trade · DGFT Verified

Nivira Exports is an Indian pharmaceutical exporter with a total trade value of $1.1M across 4 products in 2 therapeutic categories. Based on 206 verified export shipments from Indian Customs (DGFT) records, Nivira Exports is the #1 Indian exporter in 3 products including Osimertinib, Ustekinumab, Ibrutinib. Top exports include Osimertinib ($347.1K), Ustekinumab ($299.9K), Daratumumab ($255.1K).

Nivira Exports — Export Portfolio & Destination Treemap

Nivira Exports pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Nivira Exports? — Company Overview & Market Position

Established in September 2018, Nivira Exports is a licensed pharmaceutical wholesaler headquartered in Mumbai, India. The company specializes in exporting a diverse range of healthcare products, including human and veterinary medicines, dental products, surgical items, and diagnostics. Nivira Exports has built a reputation for delivering quality and affordable healthcare solutions, serving pharmaceutical wholesalers across various geographies.

The company is led by Mr. Viral Lukka, the proprietor, who brings over 20 years of experience in the pharmaceutical industry. Under his leadership, Nivira Exports has expanded its global footprint, supplying medicines to countries in South America, Europe, the UK, and several Asian nations.

Nivira Exports operates as a micro enterprise, as classified in the financial year 2024-25. The company's registered office is located at Unit No 808, 8th Floor, B2B Centre Co-Op Soc Premises Ltd, Kachpada, Malad West, Mumbai 400064, Maharashtra, India.

What Does Nivira Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Osimertinib$347.1K

Product Portfolio — Top 4 by Export Value

Nivira Exports exports 4 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Osimertinib	Advanced Oncology	$347.1K	52	31.9%	1
2	Ustekinumab	Biologics & Immunotherapy	$299.9K	61	23.6%	1
3	Daratumumab	Advanced Oncology	$255.1K	33	19.1%	2
4	Ibrutinib	Advanced Oncology	$239.9K	60	23.8%	1

Nivira Exports exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $1.1M. The company is the #1 Indian exporter in 3 products: Osimertinib, Ustekinumab, Ibrutinib. The top category is Advanced Oncology (73.7% of portfolio), followed by Biologics & Immunotherapy (26.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Nivira Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Nivira Exports sources its pharmaceutical products from manufacturers accredited with WHO-GMP, EU-GMP, US-FDA, and UK-MHRA approvals. This extensive network ensures that the company can manufacture, register products, and provide dossiers as per specific requirements.

3Key Leadership

Mr. Viral Lukka serves as the proprietor of Nivira Exports, bringing over two decades of experience in the pharmaceutical industry. His leadership has been instrumental in the company's growth and expansion into international markets.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Nivira Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Nivira Exports has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company sources products from manufacturers accredited with WHO-GMP, EU-GMP, US-FDA, and UK-MHRA approvals, facilitating market access in these regions.

2Emerging Markets

Nivira Exports has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, including WHO prequalification, has enabled it to penetrate these markets effectively.

3Geographic Strategy

Nivira Exports has strategically diversified its geographic presence, reducing concentration risk by serving a wide range of countries across continents. This global approach aligns with the company's mission to meet unmet pharmaceutical needs worldwide.

TransData Nexus Research · FDA, EMA, WHO, MHRA, TGA databasesMar 2026

Nivira Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Nivira Exports sources products from manufacturers accredited with US-FDA approvals, ensuring compliance with FDA regulations. The company's adherence to international quality standards facilitates market access in the United States.

2WHO & EU GMP

Nivira Exports sources products from manufacturers accredited with WHO-GMP and EU-GMP certifications, ensuring compliance with international quality standards. This adherence facilitates market access in various regions, including the European Union.

3CDSCO & Indian Regulatory

Nivira Exports holds a Wholesale Drug License (Form 20B and Form 21B) issued by the FDA, India, and is registered with the Directorate General of Foreign Trade (DGFT), India. These licenses and registrations enable the company to operate within the regulatory framework of India.

4Recent Regulatory Actions

Nivira Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Nivira Exports operates in a competitive landscape with several pharmaceutical exporters in India. The company's focus on sourcing products from internationally accredited manufacturers and its global reach position it favorably in the market. However, competition from other exporters with similar product portfolios and market access remains a consideration.

2Key Differentiators

Nivira Exports differentiates itself through its extensive network of suppliers and distributors, enabling it to source products at competitive prices. The company's commitment to quality, timely deliveries, and adherence to international standards further strengthen its competitive position.

3Strategic Position

Nivira Exports is strategically positioned as a pharmaceutical wholesaler with a diverse product portfolio, including human and veterinary medicines, dental products, surgical items, and diagnostics. The company's focus on sourcing from internationally accredited manufacturers and its global market presence align with its mission to meet unmet pharmaceutical needs worldwide.

Buyer Due Diligence Brief — Evaluating Nivira Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Nivira Exports maintains a robust track record in sourcing products from manufacturers accredited with WHO-GMP, EU-GMP, US-FDA, and UK-MHRA approvals. The company's export volume and consistency are supported by its extensive network of suppliers and distributors, ensuring reliable product availability.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Nivira Exports:

FDA Approval: Confirm that the products are sourced from manufacturers with US-FDA approvals.

WHO-GMP and EU-GMP Certifications: Ensure that the products meet international quality standards by verifying WHO-GMP and EU-GMP certifications.

ISO Certifications: Check for ISO certifications to assess the company's commitment to quality management systems.

These certifications can typically be verified through the respective regulatory bodies or by requesting documentation directly from Nivira Exports.

Frequently Asked Questions — Nivira Exports

How many pharmaceutical products does Nivira Exports export from India?

Nivira Exports exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Osimertinib ($347.1K), Ustekinumab ($299.9K), Daratumumab ($255.1K), Ibrutinib ($239.9K). Total export value is $1.1M.

What is Nivira Exports's total pharmaceutical export value?

Nivira Exports's total pharmaceutical export value is $1.1M, based on 206 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Nivira Exports the #1 Indian exporter?

Nivira Exports is the #1 Indian exporter in 3 products: Osimertinib (31.9% market share), Ustekinumab (23.6% market share), Ibrutinib (23.8% market share).

What therapeutic categories does Nivira Exports cover?

Nivira Exports exports across 2 therapeutic categories. The largest are Advanced Oncology (73.7%, 3 products), Biologics & Immunotherapy (26.3%, 1 products).

Get Full Nivira Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.